Source: BBC Health; Journal Cancer Research
Tamoxifen (an estrogen blocker) is currently the most prescribed drug to fight breast cancer recurrence. However up to 1/3 of women do not respond to Tamoxifen. The reasons for this are not completely known as of this post but are believed to lie in a gene -FGFR1.
Researchers are now working on methods to “switch off” the FGFR1 gene so that the therapeutic effects of Tamoxifen may be realized in greater numbers. 1 out of every 10 breast cancer survivors have the FGFR1 gene. There are currently a number of drugs which are known to inhibit FGFR1.
The stage is now set for clinical trials. If the laboratory evidence is repeatable in the real world this could mean less recurrence of breast cancer for more women. Breast cancer is the most common disease causing death for women in the US and in the UK.
~Posted by D.M. Schwadron, Esquire